Skip to main content
. Author manuscript; available in PMC: 2014 Mar 13.
Published in final edited form as: Circulation. 2013 Feb 7;127(10):1116–1127. doi: 10.1161/CIRCULATIONAHA.112.000855

Figure 3.

Figure 3

Exogenous H2S therapy prevents cardiac dilatation and dysfunction following TAC. (A) Chemical Structure of SG-1002. (B) Representative heart pictures of Sham, Vehicle (TAC+Vehicle), and SG-1002 (TAC+SG-1002) treated mice at 12 weeks of TAC. (C) The ratio of heart weight to tibia lengths. (D) The ratio of lung weight/tibia lengths. (E) Circulating BNP levels (ng/ml) at 6 and 12 weeks of TAC. (F) LVESD and (H) ejection fraction from 1 week to 12 weeks TAC. Results are expressed as mean ± SEM. *p<0.05 and ***p<0.001 vs. Baseline.

HHS Vulnerability Disclosure